159557-47-8

Basic information

• Product Name: HDH-PHARMA 24737
• Synonyms: HDH-PHARMA 24737;TERT-BUTYL 4-(BENZYLOXY)PIPERIDINE-1-CARBOXYLATE
• CAS NO: 159557-47-8
• Molecular Formula: C₁₇H₂₅NO₃
• Molecular Weight: 291.388
• Mol File: 159557-47-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 383.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.08±0.1 g/cm3(Predicted)
• PKA: -2.21±0.40(Predicted)
• CAS DataBase Reference: HDH-PHARMA 24737(CAS DataBase Reference)
• NIST Chemistry Reference: HDH-PHARMA 24737(159557-47-8)
• EPA Substance Registry System: HDH-PHARMA 24737(159557-47-8)

Safety Data

• Hazardous Substances Data: 159557-47-8(Hazardous Substances Data)

Usage

General Description

HDH-PHARMA 24737 is a chemical compound used in pharmaceutical and research applications. It is a potent and selective agonist for the δ-opioid receptor, producing analgesic effects without the side effects commonly associated with traditional opioid medications. HDH-PHARMA 24737 has shown promise in preclinical studies for the treatment of chronic pain and has the potential to offer a new avenue for pain management without the risk of addiction or respiratory depression. It is also being investigated for its potential use in creating novel opioid-based medications with improved safety and efficacy profiles.

Upstream product

• 100-44-7 benzyl chloride 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 100-39-0 benzyl bromide 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 76716-51-3 4-(benzyloxy)piperidine 
• 872692-21-2 L-valine 4-(benzyloxy)piperidide 
• 872692-35-8 N-tert-butoxycarbonyl-L-valine 4-benzyloxypiperidide 
• 872692-22-3 N-(2-ethoxycarbonyl)-L-valine 4-(benzyloxy)piperidide 

Relevant articles and documents

EHPATITIS B ANTIVIRAL AGENTS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS

The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.

PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE

[Problem] To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain. [Means for Solution] We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.